App-Quantinova.ai

Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

Anthony B. El-Khoueiry - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

Davide Melisi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

LY2157299

Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.

Charles S. Fuchs - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Adrucil injection

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).

Crystal Shereen Denlinger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Trastuzumab

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

Bruno Sangro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT).

Tamara Sauri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs).

Angela Lamarca - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal neuroendocrine carcinomas

N/A

Pathological response to neoadjuvant gemcitabine plus nabpaclitaxel in pancreatic adenocarcinoma to improve survival.

Rafael Alvarez-Gallego - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma.

Fernando Rivera - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.

Andrea Wang-Gillam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

5-fluorouracil + leucovorin

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: Results from the phase I/II CheckMate 032 study.

Padmanee Sharma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Nivolumab

Updated efficacy from IMvigor210: Atezolizumab in platinum treated locally advanced/metastatic urothelial carcinoma (mUC).

Robert Dreicer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Atezolizumab

Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.

Sumanta K. Pal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

BGJ-398

Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)SOGUG 2011-02.

Albert Font - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Carboplatin

Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).

Russell Bailey McBride - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).

J. Connor Wells - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

N/A

Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).

Thomas Powles - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.

Bernard J. Escudier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: a Spanish Oncology Genitourinary Group (SOGUG) study.

Xavier Garcia del Muro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Interferon

Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).

A. Oliver Sartor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabazitaxel

Filters

24923 Abstracts